Dimetindene

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 443476699

| IUPAC_name = N,N-Dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethan-1-amine

| image = Dimetindene.svg

| width = 200

| chirality = Racemic mixture

| tradename = Fenistil

| Drugs.com = {{drugs.com|international|dimethindene}}

| pregnancy_category =

| legal_AU = S4

| legal_UK = GSL

| routes_of_administration = Oral, topical

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 5636-83-9

| CAS_supplemental = {{CAS|3614-69-5}}

| ATC_prefix = D04

| ATC_suffix = AA13

| ATC_supplemental = {{ATC|R06|AB03}}

| PubChem = 21855

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB08801

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 20541

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 661FH77Z3P

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D07853

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 22108

| C=20 | H=24 | N=2

| smiles = n1ccccc1C(C=3c2ccccc2CC=3CCN(C)C)C

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = MVMQESMQSYOVGV-UHFFFAOYSA-N

}}

Dimetindene, also sold under the brand name Fenistil, is an antihistamine/anticholinergic. It is a first generation{{cite journal | vauthors = Fromer LM, Ortiz GR, Dowdee AM | title = Assessment of Patient Attitudes About Mometasone Furoate Nasal Spray: The Ease-of-Use Patient Survey | journal = The World Allergy Organization Journal | volume = 1 | issue = 9 | pages = 156–159 | date = September 2008 | pmid = 23282579 | pmc = 3651039 | doi = 10.1186/1939-4551-1-9-145 | doi-access = free }} selective H1 antagonist.{{Cite web|url=https://www.drugs.com/international/dimetindene.html|title=Dimetindene|website=Drugs.com}} Dimetindene is an atypical first generation H1 antagonist as it only minimally{{cite journal | vauthors = Noguchi S, Inukai T, Kuno T, Tanaka C | title = The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking | journal = Physiology & Behavior | volume = 51 | issue = 6 | pages = 1123–1127 | date = June 1992 | pmid = 1353628 | doi = 10.1016/0031-9384(92)90297-f | s2cid = 29562845 }} passes across the blood–brain barrier.

Dimetindene is also an M2 receptor antagonist.{{cite journal | vauthors = Matsumoto Y, Miyazato M, Furuta A, Torimoto K, Hirao Y, Chancellor MB, Yoshimura N | title = Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats | journal = Urology | volume = 75 | issue = 4 | pages = 862–867 | date = April 2010 | pmid = 20156651 | pmc = 2871158 | doi = 10.1016/j.urology.2009.12.013 }}

It was patented in 1958 and came into medical use in 1960.{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=547 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA547 |language=en}}